HCMHutchmedNot started yet
HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 210 (planned)
- Started
- Nov 2026
- Main results expected
- Mar 2032
- Fully finished
- Sep 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PFS assessed by BIRC (according to Response Assessment in Neuro-Oncology [RANO] 2.0 criteria)
Measured over: Up to approximately 30 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07912398 · record last updated 2026-11-03 · checked 2026-11-09 15:36 UTC